Changes to This Summary (12/05/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that a meta-analysis of case-control studies that focused on MDM2 (T309G) and prostate cancer risk revealed no association (cited Chen et al. as reference 163).
Added text about a validation study from the International Consortium of Prostate Cancer Genetics that confirmed HOXB13 as a susceptibility gene for prostate cancer risk; the G84E mutation was also significantly overtransmitted from parents to affected offspring (cited Xu et al. as reference 37).
Added text to state that one population-based, case-control study from the United States confirmed the association of the G84E mutation with prostate cancer and reported a suggestive association with aggressive disease (cited Stott-Miller et al. as reference 43).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.